The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
Abstract
Summary: Objective. To assess the safety and efficacy of a fixed dose of recombinant activated factor VII (rFVIIa; NovoSeven™) in the home setting for mild to moderately severe joint, muscle, and mucocutaneous bleeding episodes in patients with haemophilia A or B with inhibitors. Design. Multicentre, open-label, single arm, phase III study of one year duration. Methods. Patients or their caregivers administered up to three doses of rFVIIa (90 μg/kg i.v.) at 3 h intervals within 8 h of the onset of a mild to moderate bleeding episode. Once the subject considered that rFVIIa had been “effective” with regard to haemostasis (after 1-3 injections), one further (maintenance) dose of rFVIIa was administered. Results. Of 60 patients enrolled, 56 experienced at least one bleed, and 46 completed the one year study. 614 of 877 bleeds (70%) were evaluable according to protocol definitions. Haemostasis was rated as “effective” in 92% (566/614) of evaluable bleeds after a mean of 2.2 injections. For successfully treated episodes, the time from onset of bleeding until administration of the first injection was 1.1 ± 2.0 h (mean ± SD). Twenty-four hours after initial successful response, haemostasis was reported as having been maintained in 95% of cases. Efficacy was comparable for muscle, joint and target joint, and muco-cutaneous bleeding episodes. In an intent-to-treat analysis of all 877 bleeding events, efficacy outcomes were equivalent to the evaluable bleeds, with an effective response in 88% of treated episodes. Treatment-related adverse events occurred in 32 (3% of all) bleeding episodes and consisted of re-bleeds/new bleeds in more than 50% (18/32) of these events. A single episode of superficial thrombophlebitis was the only thrombotic complication encountered, and there were no patient withdrawals due to adverse events. Development of FVII(a) antibodies could not be detected, and hypersensitivity reactions to rFVIIa were not reported. Conclusion. rFVIIa is effective and well tolerated when used in the home setting to treat mild to moderate bleeding episodes in patients with haemophilia A or B with inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
Self-citationThe Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study
Hay, C. R. M., Negrier, C., & Ludlam, C. A. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1665434 · Cited by 344
Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P., & the members of the French FEIBA study group (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656122 · Cited by 276
Factor VIIa in the treatment of haemophilia
Hedner, U. K. E. (1990) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199008000-00009 · Cited by 128
Lusher, J. M., Blatt, P., Penner, J. A., Aledort, L. M., Levine, P., Gc, W., Warrier, A., & Whitehurst, D. (1983) · Blood · doi:10.1182/blood.v62.5.1135.1135 · Cited by 121
Self-citationMajor Surgery in Haemophilic Patients with Inhibitors Using Recombinant Factor VIla
Ingerslev, J., Freidman, D., Gastineau, D. A., Gilchrist, G., Johnsson, H., Lucas, G., McPherson, J., Preston, E., Scheibel, E., & Shuman, M. (2009) · Haemostasis · doi:10.1159/000217252 · Cited by 118
Self-citationInhibitors in hemophilia patients: Current status and management
Aledort, L. M. (1994) · American Journal of Hematology · doi:10.1002/ajh.2830470312 · Cited by 86
Self-citationPhysical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85.
Smit, C., Rosendaal, F. R., Varekamp, I., Bröcker-Vriends, A. H. J. T., van Dijck, H., Suurmeijer, T. P. B. M., & Briët, E. (1989) · BMJ · doi:10.1136/bmj.298.6668.235 · Cited by 69
Hemophilia Home Treatment:Economic Analysis and Implications for Health Policy
Ross‐Degnan, D., Soumerai, S. B., Avorn, J., Bohn, R. L., Bright, R., & Aledort, L. M. (1995) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300006930 · Cited by 30
Self-citation
Cited by
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Astermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J., Berntorp, E., & for the FENOC Study Group (2007) · Blood · doi:10.1182/blood-2006-04-017988 · Cited by 473
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
Delgado, J., Jimenez‐Yuste, V., Hernandez‐Navarro, F., & Villar, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04162.x · Cited by 469
Abshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Metadata
- Authors
- Aledort, L., Beardsley, D., Cooper, H., Davignon, G., Ewenstein, B., Gilchrist, G., Gill, J., Glader, B., Hoots, W. K., Kisker, C. T., Lusher, J., Rosenfield, C., Shapiro, A., Smith, H., Taft, E., & Key, N.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1998
- Volume
- 80
- Issue
- 12
- Pages
- 912-918
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1912089454
- Cited by
- 354
- References
- 9
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. https://app.cochat.ai/papers/10.1055/s-0037-1615388
- The paper
- Aledort, L., Beardsley, D., Cooper, H., Davignon, G., Ewenstein, B., Gilchrist, G., Gill, J., Glader, B., Hoots, W. K., Kisker, C. T., Lusher, J., Rosenfield, C., Shapiro, A., Smith, H., Taft, E., & Key, N. (1998). Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1615388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.